Cristian Hernandez-Cuevas

Mavatar is a global leader in AI-powered precision medicine, built on more than 20 years of scientific innovation. While most life science AI projects start with generic models and try to adapt them to biology, Mavatar has done the opposite- designing its AI from the ground up for biomedical decision-making. At the core is DINA (Deep Integrated Network Analysis)—a proprietary vertical AI and data-driven framework trained on harmonized transcriptomic data across tissues, diseases, and populations. Unlike generative models or general-purpose tools, DINA is engineered specifically for reasoning within complex biological systems: understanding what happens, why it happens, and what happens if we intervene. This intelligence powers two commercial platforms; - Mavatar Discovery – supporting the acceleration of drug discovery, repurposing, and trial design for pharma and researchers. - Mavatar Precision – delivering real-time, personalized treatment guidance to clinicians based on patient-specific molecular profiles. By simulating digital twins of both patients and diseases, Mavatar enables predictive matching between disease mechanisms and therapies. As medicine shifts from one-size-fits-all to highly personalized care, Mavatar is uniquely positioned to lead this transformation and capture value across a multibillion-dollar global market.

Geneprodx us a clinical laboratory devoted to the molecular diagnostic of thyroid cancer. Geneprodx developed ThyroidPrint®, a test the will prevent 88% of unnecessary surgery practiced on patients with an undetermined diagnostic. ThyroidPrint® is the only genetic test for thyroid cancer that has been validated in two independent clinical trials: USA and Chile. Geneprodx is a spin-off from the Pontifical Catholic University of Chile and is the first chilean clinical laboratory to be accredited by the College of American Patologists (CAP). Visit our ThyroidPrint® website. There you may find all the information that patients and physicians need about this test.

[Note: Rebranded to Lucira Health.] Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.

Eagle Genomics applies network science to biology. We are revealing the impact of the microbiome on humans, animals and the environment to secure a sustainable future for our food, water, soil and the health of our planet. Our mission is to deliver insight from the microbiome to profoundly change our understanding of wellness and even our fundamental assumptions about life on earth. Our platform transforms scientists’ journey to insights, unifying constellations of complex, multi-dimensional data (the data fabric) to explore and extract signals and networks of relationship, otherwise not detectable by humans alone. This is the frontier of science today and nowhere are the opportunities and challenges more significant than in the burgeoning field of the microbiome.

We are a world-class lab with more than 10 years of experience developing bacteriophage-based treatments. We have one mission: to protect the world as one health. It’s the only solution to the global burden of antibiotic resistance generated by its indiscriminate use, which affects millions of lives everyday and everywhere. In pursuit of this mission, our treatment development is 100% tailored for the efficient control of bacteria in poultry, cattle and aquaculture production systems industry. All of this is possible thanks to our staff and LEIDEN®, our AI platform based in deep epidemiological diagnostics algorithms to create effective results in bacterial population control in record time. Our production of custom solutions is rising constantly as we land in different locations throughout the globe. Let’s create a safe and sustainable future for all, because science works and we can prove it. WE SHARE ONE HEALTH. Visit us at www.phage-lab.com PhageLab® is registered as a trademark in Chile, Brazil, Peru, Mexico, Europe and United Kingdom. Leiden® is registered as a trademark in Chile, Brazil, Peru, Mexico and Thailand. Copyright © 2010 - 2023, PhageLab Chile SpA or its affiliates. All rights reserved for its own use.

Mavatar is a global leader in AI-powered precision medicine, built on more than 20 years of scientific innovation. While most life science AI projects start with generic models and try to adapt them to biology, Mavatar has done the opposite- designing its AI from the ground up for biomedical decision-making. At the core is DINA (Deep Integrated Network Analysis)—a proprietary vertical AI and data-driven framework trained on harmonized transcriptomic data across tissues, diseases, and populations. Unlike generative models or general-purpose tools, DINA is engineered specifically for reasoning within complex biological systems: understanding what happens, why it happens, and what happens if we intervene. This intelligence powers two commercial platforms; - Mavatar Discovery – supporting the acceleration of drug discovery, repurposing, and trial design for pharma and researchers. - Mavatar Precision – delivering real-time, personalized treatment guidance to clinicians based on patient-specific molecular profiles. By simulating digital twins of both patients and diseases, Mavatar enables predictive matching between disease mechanisms and therapies. As medicine shifts from one-size-fits-all to highly personalized care, Mavatar is uniquely positioned to lead this transformation and capture value across a multibillion-dollar global market.

Zentynel emerges as a convergent evolution between a group related to Fundación Ciencia y Vida (FCV) (Pablo Valenzuela, Bernardita Méndez and Cristián Hernández), along with Venturance Alternative Assets. Following a review of different industries, they identified that biotechnological entrepreneurs needed an investor specialized, along with the opportunity to provide capital and experience and thus accelerate the development and growth of this type of initiatives. We want to help close the existing investment gap with Biotechnology-based projects in Latin America, from research and local development to execution and global marketing.

Geneprodx us a clinical laboratory devoted to the molecular diagnostic of thyroid cancer. Geneprodx developed ThyroidPrint®, a test the will prevent 88% of unnecessary surgery practiced on patients with an undetermined diagnostic. ThyroidPrint® is the only genetic test for thyroid cancer that has been validated in two independent clinical trials: USA and Chile. Geneprodx is a spin-off from the Pontifical Catholic University of Chile and is the first chilean clinical laboratory to be accredited by the College of American Patologists (CAP). Visit our ThyroidPrint® website. There you may find all the information that patients and physicians need about this test.

[Note: Rebranded to Lucira Health.] Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.